ATE293883T1 - Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen - Google Patents
Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungenInfo
- Publication number
- ATE293883T1 ATE293883T1 AT97901425T AT97901425T ATE293883T1 AT E293883 T1 ATE293883 T1 AT E293883T1 AT 97901425 T AT97901425 T AT 97901425T AT 97901425 T AT97901425 T AT 97901425T AT E293883 T1 ATE293883 T1 AT E293883T1
- Authority
- AT
- Austria
- Prior art keywords
- antioxidants
- liver disease
- cholestatic liver
- treat cholestatic
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1004996P | 1996-01-16 | 1996-01-16 | |
PCT/US1997/000403 WO1997025864A1 (en) | 1996-01-16 | 1997-01-15 | Use of antioxidant agents to treat cholestatic liver disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE293883T1 true ATE293883T1 (de) | 2005-05-15 |
Family
ID=21743557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97901425T ATE293883T1 (de) | 1996-01-16 | 1997-01-15 | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen |
Country Status (7)
Country | Link |
---|---|
US (1) | US6069167A (de) |
EP (1) | EP0893949B1 (de) |
AT (1) | ATE293883T1 (de) |
AU (1) | AU724620B2 (de) |
CA (1) | CA2242991C (de) |
DE (1) | DE69733132D1 (de) |
WO (1) | WO1997025864A1 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9722361D0 (en) * | 1997-10-24 | 1997-12-17 | Pharma Nord Uk Ltd | Pharmaceutical formulation for treating liver disorders |
US6616942B1 (en) * | 1999-03-29 | 2003-09-09 | Soft Gel Technologies, Inc. | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing |
US6623734B2 (en) | 2000-06-22 | 2003-09-23 | Soft Gel Technologies, Inc. | Super absorption coenzyme Q10 |
US6855733B2 (en) * | 2001-01-24 | 2005-02-15 | Soft Gel Technologies, Inc. | Formulation and manufacturing process for coenzyme Q10 soft gel capsules |
US6596762B2 (en) | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
US20080089877A1 (en) * | 2003-08-14 | 2008-04-17 | Udell Ronald G | Super Absorption Coenzyme Q10 |
US20070026090A1 (en) * | 2003-09-05 | 2007-02-01 | Oren Tirosh | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
WO2005032278A1 (en) * | 2003-09-29 | 2005-04-14 | Soft Gel Technologies, Inc. | SOLUBILIZED CoQ-10 |
US8124072B2 (en) * | 2003-09-29 | 2012-02-28 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US7169385B2 (en) * | 2003-09-29 | 2007-01-30 | Ronald G. Udell | Solubilized CoQ-10 and carnitine |
US20050074445A1 (en) * | 2003-10-01 | 2005-04-07 | Papas Andreas M. | Alpha-tocopherol treatment for cystic fibrosis |
US20050107465A1 (en) * | 2003-10-01 | 2005-05-19 | Papas Andreas M. | Composition for treating inflammatory bowel disease |
TW200524579A (en) * | 2003-11-28 | 2005-08-01 | Kaneka Corp | Composition for protecting liver functions |
US7790190B2 (en) * | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
US7284385B2 (en) * | 2004-09-16 | 2007-10-23 | Hess Spencer W | Pre-dried air reactivation for diesel fuel heated dessicant reactivator |
DE102004049339A1 (de) * | 2004-10-08 | 2006-04-13 | Basf Ag | Verfahren zur Reinigung von phosphorhaltigen Chelat-Liganden |
AU2006219823A1 (en) * | 2005-03-02 | 2006-09-08 | Metanomics Gmbh | Process for the production of fine chemicals |
US20070167422A1 (en) * | 2006-01-18 | 2007-07-19 | Yu Kwok S | Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin |
US8343541B2 (en) * | 2007-03-15 | 2013-01-01 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
US8795627B2 (en) | 2007-03-21 | 2014-08-05 | Raptor Pharmaceuticals Inc. | Treatment of liver disorders by administration of RAP conjugates |
EP2132224B1 (de) * | 2007-03-21 | 2011-12-28 | Raptor Pharmaceutical Inc | Cyclische rezeptor-assoziierte-proteine (rap)-peptide |
WO2010040058A1 (en) | 2008-10-02 | 2010-04-08 | George Zabrecky | Methods and formulations for treating chronic liver disease |
SG190029A1 (en) | 2010-11-08 | 2013-06-28 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
CN105287604B (zh) * | 2010-11-08 | 2019-07-09 | 阿尔比里奥公司 | 含ibat抑制剂和胆汁酸结合剂的药物组合 |
CA2853285C (en) * | 2011-10-28 | 2020-05-05 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
EP3012252A1 (de) | 2014-10-24 | 2016-04-27 | Ferring BV | Kristalline Form von elobixibat |
US20160367620A1 (en) | 2015-06-19 | 2016-12-22 | Harry B. Demopoulos | Glutathione |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
WO2019245449A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
EP4069361B1 (de) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren |
JP2023504647A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
EP4069247A1 (de) | 2019-12-04 | 2022-10-12 | Albireo AB | Benzothiadiazepinverbindungen und ihre verwendung als gallensäuremodulatoren |
FI4069360T3 (fi) | 2019-12-04 | 2024-02-20 | Albireo Ab | Bentsotia(di)atsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina |
CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984001899A1 (en) * | 1982-11-16 | 1984-05-24 | Georges Motschan | New utilization of a unique vitamin or a combination of various vitamins |
EP0528950B1 (de) * | 1990-05-16 | 1996-09-11 | Zbigniew Walaszek | Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen |
US5308627A (en) * | 1990-08-07 | 1994-05-03 | Umbdenstock Jr Anthony J | Nutritional supplement for optimizing cellular health |
EP0746202A4 (de) * | 1992-01-06 | 1997-06-25 | Health Maintenance Programs | Pharmazeutisch aktive antioxidant enthaltende zusammensetzung und verfahren zu ihrer verwendung in der vorbeugung und behandlung vom restenosis nach angioplastie |
CN1080855A (zh) * | 1993-05-22 | 1994-01-19 | 黎均耀 | 维生素矿物质防癌复方 |
DE4322070A1 (de) * | 1993-07-02 | 1995-01-12 | Ploch Eva Marina | Umweltkapsel |
-
1997
- 1997-01-15 US US08/784,247 patent/US6069167A/en not_active Expired - Fee Related
- 1997-01-15 DE DE69733132T patent/DE69733132D1/de not_active Expired - Lifetime
- 1997-01-15 WO PCT/US1997/000403 patent/WO1997025864A1/en active IP Right Grant
- 1997-01-15 AU AU15329/97A patent/AU724620B2/en not_active Expired
- 1997-01-15 CA CA002242991A patent/CA2242991C/en not_active Expired - Lifetime
- 1997-01-15 EP EP97901425A patent/EP0893949B1/de not_active Expired - Lifetime
- 1997-01-15 AT AT97901425T patent/ATE293883T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0893949A1 (de) | 1999-02-03 |
AU724620B2 (en) | 2000-09-28 |
US6069167A (en) | 2000-05-30 |
DE69733132D1 (de) | 2005-06-02 |
CA2242991A1 (en) | 1997-07-24 |
WO1997025864A1 (en) | 1997-07-24 |
EP0893949A4 (de) | 2002-01-02 |
EP0893949B1 (de) | 2005-04-27 |
CA2242991C (en) | 2007-07-24 |
AU1532997A (en) | 1997-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE293883T1 (de) | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen | |
ATE198044T1 (de) | Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges | |
DE69625691D1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
UA26213C2 (uk) | Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові | |
CY1111912T1 (el) | Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
DE69509544D1 (de) | Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten | |
DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
DK0920309T3 (da) | Konjugeret linolensyre til bevaring eller forøgelse af mineralindhold i knogler | |
DE69526937T2 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
ATE303817T1 (de) | Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
DE69739970D1 (de) | Methode zur behandlung sexueller fehlfunktionen | |
EA199700151A1 (ru) | Композиция для чрескожного введения | |
DE69725879D1 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
DE69729004D1 (de) | Photodynamische therapie zur behandlung von osteosrthritis | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
ATE332688T1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
ATE234614T1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
DE69319341D1 (de) | Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion | |
HUP9900007A2 (hu) | Készítmény baromfialom kezelésére | |
ATE235249T1 (de) | Die von morphogenen peptiden hervorgerufene wiederherstellung von gewebe aus sinneszellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |